Open an account

Celcuity

CELC · NASDAQ

$60.00+$2.88 (+5.04%)TodayMarket closed ·
Prev close $57.12

About CELC

Celcuity, Inc. operates as a cellular analysis company. The company is headquartered in Minneapolis, Minnesota and currently employs 155 full-time employees. The company went IPO on 2017-09-20. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.

Employees
155
Headquarters
Minneapolis, Minnesota
Listed
Sep 20, 2017
Sector
Health Care
Industry
Biotechnology
Website
celcuity.com

CELC key statistics

Market cap
2.94B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.73M
Volume
2.38M
Open price
$57.12
High today
$62.56
Low today
$56.81
52 Week high
$151.02
52 Week low
$53.54

Celcuity (CELC) at a glance

Celcuity (CELC) last traded at $60.00, with a market cap of 2.94B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $56.81 and $62.56. The current price is 5.6% above the day's low and 4.1% below its high.

Volume so far is 2.38M shares, above the average of 1.73M shares a day.

Over the past year Celcuity has ranged from $53.54 to $151.02, and now sits 7% of the way up that range.

Celcuity met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$1.23 per share against an estimate of -$1.19.

The average analyst price target is $156.47, 160.8% above the current price, from 11 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 11 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 13 analystsAvg $156.47
Low
$111.10
Now
$60.00
High
$185.85

CELC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 7.8% on average.

  1. Q3 FY24: reported -$0.70 per share against an estimate of -$0.6659
  2. Q4 FY24: reported -$0.85 per share against an estimate of -$0.7227
  3. Q1 FY25: reported -$0.86 per share against an estimate of -$0.8789
  4. Q2 FY25: reported -$1.04 per share against an estimate of -$0.902
  5. Q3 FY25: reported -$0.92 per share against an estimate of -$1.03
  6. Q4 FY25: reported -$0.97 per share against an estimate of -$1.06
  7. Q1 FY26: reported -$0.97 per share against an estimate of -$1.07
  8. Q2 FY26: reported -$1.23 per share against an estimate of -$1.19

CELC news

  • 10 Health Care Stocks With Whale Alerts In Today’s Session

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC

  • Press releaseGlobe Newswire

    Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the Firm

  • Press releaseBusiness Wire

    CELC SHAREHOLDER ALERT: Celcuity Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

  • Press releaseBusiness Wire

    CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law

  • Press releasePRNewswire

    CELC Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsnOn Behalf of Investors of Celcuity Inc. - CELC

Similar companies

Companies in the same industry as Celcuity

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.